Investigating cGAS inhibitors for treating Alzheimer's disease
cGAS inhibitors for Alzheimer's disease treatment
This study is looking at how a new treatment that targets certain brain cells might help improve memory and reduce inflammation in people with Alzheimer's disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11088880 on NIH RePORTER |
What this research studies
This research focuses on Alzheimer's disease, the most common form of dementia in the elderly, by exploring the role of cGAS inhibitors in addressing tau pathology, which is critical for memory decline. The study aims to understand how targeting microglial cells, which are immune cells in the brain, can lead to new treatment options. By utilizing small molecule inhibitors to block cGAS, the research seeks to reduce neuroinflammation and improve cognitive function in Alzheimer's patients. The approach is based on previous findings that genetic ablation of cGAS can protect against cognitive deficits in animal models of tau pathology.
Who could benefit from this research
Good fit: Ideal candidates for this research include elderly individuals diagnosed with Alzheimer's disease, particularly those exhibiting tau pathology.
Not a fit: Patients with early-stage Alzheimer's disease or those without significant tau pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options that significantly improve memory and cognitive function in Alzheimer's disease patients.
How similar studies have performed: While targeting tau pathology has been challenging, this approach of inhibiting cGAS is novel and has not been extensively tested in clinical settings.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Sinha, Subhash C — Weill Medical Coll of Cornell Univ
- Study coordinator: Sinha, Subhash C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.